Perspective Therapeutics (CATX) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Indaptus Therapeutics (INDP) over the past year, losing 29.1% versus a loss of 38.8%. Over five years, CATX leads with a -60.3% price change compared with -99.0% for INDP. Indaptus Therapeutics is the larger company by market cap ($315.8 million vs $309.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | INDP |
|---|---|---|
| Share price | $2.71 | $2.37 |
| Market cap | $309.35M | $315.78M |
| 1-day change | +10.16% | +4.87% |
| YTD return | -10.55% | -22.34% |
| 1-year return | -29.11% | -38.75% |
| 5-year return | -60.32% | -98.97% |
| EPS (TTM) | $-1.33 | $-6.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $5.96 |
| 52-week low | $1.96 | $0.92 |
| Distance from 52-week high | -56.01% | -60.23% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +353.51% | — |
| Average volume | 1.67M | 829.14K |
| Shares outstanding | 114.15M | 133.24M |
| Employees | 163 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CATX vs INDP FAQ
Which is bigger, Perspective Therapeutics or Indaptus Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $315.78M compared with $309.35M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or INDP?
CATX returned -29.11% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.